News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Transgenomic, Inc. (TBIO) and New York University Collaborate on Lung Cancer Study Using ICE COLD-PCR for Blood-Based Mutation Detection



9/4/2012 10:43:47 AM

OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (OTCBB: TBIO) today announced that it has begun a collaboration with NYU Langone Medical Center to employ its ultra-high sensitivity ICE COLD-PCR mutation detection technology to better understand molecular events that drive non-small cell lung cancer and impact response to existing and novel therapies. The joint study will focus on the detection of cancer-associated mutations in the blood of patients with surgically operable early stage lung cancer, the stage where it is most curable and amenable to treatment.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES